|22nd September 2020||Advisors Llc Perceptive||1,644,785||Conversion of derivative||$0.00|
|22nd September 2020||Advisors Llc Perceptive||1,058,824||Open or private purchase||$17.00||$18,000,008.00|
|15th September 2020||Advisors Llc Perceptive||2,911,764||Open or private purchase||$4.25||$12,374,997.00|
|14th September 2020||Advisors Llc Perceptive||400,000||Open or private purchase||$40.00||$16,000,000.00|
|14th September 2020||Advisors Llc Perceptive||1,800,000||Open or private purchase||$11.00||$19,800,000.00|
|10th September 2020||Advisors Llc Perceptive||200,000||Open or private purchase||$11.24||$2,248,000.00|
|16th July 2020||Richard Scott Struthers||17,500||Open or private sale||$14.46||$253,107.75|
|15th July 2020||Richard Scott Struthers||17,500||Open or private sale||$15.30||$267,722.00|
|9th July 2020||Advisors Llc Perceptive||3,200,000||Open or private purchase||$4.25||$13,600,000.00|
|6th July 2020||Matthew K Fust||6,181||Exercise of derivative||$21.00||$129,801.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.
Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen Betz in 2008.